Back to top

crispr: Archive

Zacks Equity Research

Intellia's (NTLA) NTLA-5001 Gets FDA Orphan Drug Tag for AML

Intellia's (NTLA) investigational gene-editing therapy, NTLA-5001, gets an Orphan Drug tag from the FDA for AML.

REGNNegative Net Change VRTXNegative Net Change BDSIPositive Net Change NTLAPositive Net Change

Zacks Equity Research

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

REGNNegative Net Change VRTXNegative Net Change ABUSPositive Net Change NTLAPositive Net Change

Zacks Equity Research

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

REGNNegative Net Change VRTXNegative Net Change TBPHPositive Net Change NTLAPositive Net Change

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

VRTXNegative Net Change TBPHPositive Net Change ADAPNegative Net Change CRSPPositive Net Change

Zacks Equity Research

CRISPR (CRSP) to Report Q4 Earnings: What's in the Cards?

On CRISPR Therapeutics' (CRSP) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates, especially its lead candidate CTX001.

VRTXNegative Net Change CRSPPositive Net Change VIRPositive Net Change